Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;60(5):432-439.
doi: 10.1007/s00108-019-0588-5.

[Immunoglobulin A nephropathy]

[Article in German]
Affiliations
Review

[Immunoglobulin A nephropathy]

[Article in German]
C Seikrit et al. Internist (Berl). 2019 May.

Abstract

Immunoglobulin A nephropathy (IgAN) is the most prevalent primary form of glomerulopathy in the western world. The pathogenetic relevance of autoimmune mechanisms, genetics and environmental or nutritional factors is not fully established. The majority of IgAN patients present with mild symptoms; however, the exact prognosis of the individual IgAN course is often difficult to predict. In approximately one third of the patients the disease remains on a stable benign course, whereas approximately 30% may develop end-stage renal disease. Risk factors for disease progression are a persistent microhematuria and proteinuria >1 g/day, arterial hypertension and the extent of tubulointerstitial fibrosis at the time of diagnosis. Recent genome-wide association studies (GWAS) identified numerous risk alleles, which can contribute to the pathophysiology of IgAN. The so-called gut-kidney axis as well as the complement system and genes that are linked to mucosal immunity appear to be important for the manifestation of the disease. Intensive supportive care should be initiated as first-line treatment and only rare cases with progressive features require treatment with corticosteroids. Other immunosuppressive treatment strategies have currently no indications for IgAN. Future approaches might be the use of local budesonide or the inhibition of lymphocyte activation.

Keywords: Corticosteroids; Glomerulonephritis; IgA nephropathy, pathophysiology; Immunosuppression; Risk factors.

PubMed Disclaimer

References

    1. J Nephrol. 2016 Feb;29(1):1-4 - PubMed
    1. J Am Soc Nephrol. 2011 Apr;22(4):752-61 - PubMed
    1. Kidney Int. 2009 Sep;76(5):546-56 - PubMed
    1. J Am Soc Nephrol. 2018 Nov;29(11):2745-2754 - PubMed
    1. Benef Microbes. 2013 Mar 1;4(1):67-82 - PubMed

MeSH terms

Substances

LinkOut - more resources